CL2009000089A1 - Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras. - Google Patents
Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras.Info
- Publication number
- CL2009000089A1 CL2009000089A1 CL2009000089A CL2009000089A CL2009000089A1 CL 2009000089 A1 CL2009000089 A1 CL 2009000089A1 CL 2009000089 A CL2009000089 A CL 2009000089A CL 2009000089 A CL2009000089 A CL 2009000089A CL 2009000089 A1 CL2009000089 A1 CL 2009000089A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- synthesis
- biphenyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
LA INVENCIÓN SE REFIERE A UN PROCESO PARA PRODUCIR INHIBIDORES DE NEP O PRO-FÁRMACOS<br /> DE LOS MISMOS, EN PARTICULAR INHIBIDORES DE NEP QUE COMPRENDEN UNA ESTRUCTURA BASE DE<br /> ÁCIDO Y-AMINO-Ó-BIFENIL-A-METIL-ALCANOICO, O DE UN ÉSTER DE ÁCIDO. CON DETALLE, LOS<br /> PROCESOS, DE ACUERDO CON LA PRESENTE INVENCION, SE RELACIONAN POR ÚLTIMO CON LA<br /> SÍNTESIS DE INTERMEDIARIOS PARA PREPARAR LOS INHIBIDORES DE NEP ANTERIORES, ES DECIR,<br /> LOS COMPUESTOS DE ACUERDO CON LA FÓRMULA (1), O UNA SAL DE LOS MISMOS QUE SE OBTIENE<br /> A PARTIR DE LA REDUCCIÓN DE UN COMPUESTO INTERMEDIARIO DE FÓRMULA (2) COMO SE MUESTRA<br /> A CONTINUACIÓN:<br /> EN DONDE R1 Y R2 SON, INDEPENDIENTEMENTE UNO DEL OTRO, HIDROGENO O UN GRUPO PROTECTOR DE NITROGENO,<br /> Y R3 ES UN GRUPO CARBOXILO O UN GRUPO ESTER, DE PREFERENCIA UN GRUPO CARBOXILO O ALQUIL-ESTER.<br /> COMPLEMENTARIAMENTE LA INVENCION SE REFIERE A LOS COMPUESTOS INTERMEDIARIOS DE DICHOS<br /> INHIBIDORES DE NEP ASI COMO A LA SINTESIS DE DICHOS COMPUESTOS INTERMEDIARIOS.<br />
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08150353 | 2008-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000089A1 true CL2009000089A1 (es) | 2010-01-22 |
Family
ID=40758693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000089A CL2009000089A1 (es) | 2008-01-17 | 2009-01-16 | Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras. |
Country Status (29)
Country | Link |
---|---|
US (4) | US8580974B2 (es) |
EP (1) | EP2245009B1 (es) |
JP (2) | JP5739667B2 (es) |
KR (1) | KR101587668B1 (es) |
CN (2) | CN103483236B (es) |
AR (1) | AR070176A1 (es) |
AU (1) | AU2009204759B2 (es) |
BR (1) | BRPI0906764A2 (es) |
CA (1) | CA2711529C (es) |
CL (1) | CL2009000089A1 (es) |
CO (1) | CO6290677A2 (es) |
EC (1) | ECSP10010405A (es) |
ES (1) | ES2602564T3 (es) |
GT (1) | GT201000211A (es) |
HU (1) | HUE030606T2 (es) |
IL (1) | IL206664A0 (es) |
MA (1) | MA31951B1 (es) |
MX (1) | MX2010007842A (es) |
MY (1) | MY169425A (es) |
NZ (2) | NZ600119A (es) |
PE (1) | PE20091364A1 (es) |
PL (1) | PL2245009T3 (es) |
PT (1) | PT2245009T (es) |
RU (2) | RU2513521C2 (es) |
SG (1) | SG187491A1 (es) |
SI (1) | SI2245009T1 (es) |
TN (1) | TN2010000304A1 (es) |
TW (1) | TWI422370B (es) |
WO (1) | WO2009090251A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR070176A1 (es) * | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
US8450496B2 (en) * | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
AR076706A1 (es) | 2009-05-28 | 2011-06-29 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de neprilisina |
KR101442897B1 (ko) | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
BR112012006406A2 (pt) | 2009-09-23 | 2016-04-12 | Novartis Ag | "processo para a fabrição de n-acilbifenil alanina" |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
AU2011207020B2 (en) * | 2010-01-22 | 2014-04-17 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
AU2011295171B2 (en) | 2010-08-23 | 2015-01-15 | Novartis Ag | New process for the preparation of intermediates useful for the manufacture NEP inhibitors |
CN103080077B (zh) * | 2010-08-23 | 2015-06-10 | 诺华股份有限公司 | 用于制造nep抑制剂的中间体的制备工艺 |
WO2012025501A1 (en) | 2010-08-23 | 2012-03-01 | Novartis Ag | Process for the preparation of intermediates for the manufacture of nep inhibitors |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
CA2817368C (en) | 2010-12-15 | 2019-12-31 | Theravance, Inc. | Neprilysin inhibitors |
EP2651900B1 (en) | 2010-12-15 | 2015-08-19 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
JP5959065B2 (ja) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
JP5959066B2 (ja) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
WO2012166390A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
CN103748070B (zh) | 2011-05-31 | 2015-06-24 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
TWI560172B (en) * | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
WO2013181332A1 (en) | 2012-05-31 | 2013-12-05 | Theravance, Inc. | Nitric oxide donor neprilysin inhibitors |
EP2858650B1 (en) | 2012-06-08 | 2018-11-14 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
WO2013184934A1 (en) | 2012-06-08 | 2013-12-12 | Theravance, Inc. | Neprilysin inhibitors |
SI2882716T1 (sl) | 2012-08-08 | 2017-04-26 | Theravance Biopharma R&D Ip, Llc | Zaviralci neprilizina |
MX367525B (es) | 2013-02-14 | 2019-08-26 | Novartis Ag | Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep). |
US9102635B2 (en) | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
US8901169B2 (en) | 2013-03-05 | 2014-12-02 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
EP4282973A3 (en) * | 2013-11-15 | 2024-03-27 | F. Hoffmann-La Roche AG | Processes for the preparation of pyrimidinylcyclopentane compounds |
ES2718239T3 (es) | 2014-01-30 | 2019-06-28 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina |
EP3099668B1 (en) | 2014-01-30 | 2022-05-04 | Theravance Biopharma R&D IP, LLC | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
PL3218351T3 (pl) | 2014-11-14 | 2019-12-31 | Zentiva K.S. | Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377 |
ES2883557T3 (es) * | 2014-12-19 | 2021-12-09 | Basf Se | Composición para su uso en un procedimiento para la preparación de compuestos carbonílicos ópticamente activos |
MY187899A (en) | 2015-02-11 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor |
TW201632493A (zh) | 2015-02-13 | 2016-09-16 | 諾華公司 | 新穎方法 |
RU2715241C2 (ru) | 2015-02-19 | 2020-02-26 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота |
CN106146351B (zh) * | 2015-04-03 | 2020-09-11 | 博瑞生物医药(苏州)股份有限公司 | 制备联芳基取代的4-氨基-丁酸或其衍生物的方法 |
CN105061263B (zh) * | 2015-08-11 | 2017-03-15 | 苏州楚凯药业有限公司 | 一种nep抑制剂中间体的制备方法 |
CN105152980B (zh) * | 2015-09-11 | 2017-03-29 | 浙江永宁药业股份有限公司 | N‑叔丁氧羰基‑(4s)‑(对苯基苯基甲基)‑4‑氨基‑(2r)‑甲基丁酸的手性制备方法 |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
ES2830266T3 (es) | 2015-12-10 | 2021-06-03 | Novartis Ag | Compuestos intermedios para la preparación de sacubitril y su preparación |
WO2017097275A1 (en) | 2015-12-11 | 2017-06-15 | Zentiva, K.S. | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method |
RU2756223C2 (ru) | 2016-03-08 | 2021-09-28 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения |
JP6944473B2 (ja) | 2016-07-05 | 2021-10-06 | ノバルティス アーゲー | 初期サクビトリル中間体のための新規な方法 |
JP6945619B2 (ja) | 2016-08-17 | 2021-10-06 | ノバルティス アーゲー | Nep阻害剤合成のための新規な方法および中間体 |
JP7138106B2 (ja) | 2016-12-23 | 2022-09-15 | ノバルティス アーゲー | 初期サクビトリル中間体のための新規な方法 |
EP3421455B1 (en) * | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib |
CN109912508B (zh) * | 2019-04-30 | 2022-08-12 | 上海天慈国际药业有限公司 | 一种右美托咪定及其盐酸盐的制备方法 |
CN110878039A (zh) * | 2019-12-18 | 2020-03-13 | 株洲千金药业股份有限公司 | 一种沙库巴曲缬沙坦钠杂质的制备方法 |
CN115611857A (zh) * | 2022-09-09 | 2023-01-17 | 上海伍夫科技有限公司 | 一种2-甲基-5-(1-甲基吡咯烷-2-基)吡啶的制备方法 |
CN115772088A (zh) * | 2022-12-28 | 2023-03-10 | 海门瑞一医药科技有限公司 | 一种叔丁氧基(双二甲胺基)甲烷的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3164237D1 (en) | 1980-12-23 | 1984-07-19 | Air Ind | Thermo-electrical plants |
US5250552A (en) | 1991-05-09 | 1993-10-05 | Warner-Lambert Company | 3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents |
US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
EP0550313A1 (fr) | 1991-12-30 | 1993-07-07 | Synthelabo | Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse |
FR2688503B1 (fr) | 1992-03-16 | 1994-05-06 | Synthelabo | Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle]. |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
US5412102A (en) | 1994-05-27 | 1995-05-02 | Syntex (U.S.A.) Inc. | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
EP1903027A1 (en) * | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
MY151993A (en) * | 2007-01-12 | 2014-07-31 | Novartis Ag | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
CA2723671C (en) | 2007-05-10 | 2018-06-19 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
AR070176A1 (es) * | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
AU2011207020B2 (en) * | 2010-01-22 | 2014-04-17 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
WO2012025501A1 (en) * | 2010-08-23 | 2012-03-01 | Novartis Ag | Process for the preparation of intermediates for the manufacture of nep inhibitors |
AU2011295171B2 (en) * | 2010-08-23 | 2015-01-15 | Novartis Ag | New process for the preparation of intermediates useful for the manufacture NEP inhibitors |
-
2009
- 2009-01-15 AR ARP090100121A patent/AR070176A1/es unknown
- 2009-01-15 PE PE2009000047A patent/PE20091364A1/es not_active Application Discontinuation
- 2009-01-16 PT PT97020218T patent/PT2245009T/pt unknown
- 2009-01-16 MY MYPI2010003112A patent/MY169425A/en unknown
- 2009-01-16 TW TW098101721A patent/TWI422370B/zh not_active IP Right Cessation
- 2009-01-16 JP JP2010544498A patent/JP5739667B2/ja active Active
- 2009-01-16 NZ NZ600119A patent/NZ600119A/xx not_active IP Right Cessation
- 2009-01-16 AU AU2009204759A patent/AU2009204759B2/en not_active Ceased
- 2009-01-16 PL PL09702021T patent/PL2245009T3/pl unknown
- 2009-01-16 BR BRPI0906764-7A patent/BRPI0906764A2/pt not_active IP Right Cessation
- 2009-01-16 NZ NZ586657A patent/NZ586657A/en not_active IP Right Cessation
- 2009-01-16 ES ES09702021.8T patent/ES2602564T3/es active Active
- 2009-01-16 SG SG2013004098A patent/SG187491A1/en unknown
- 2009-01-16 MX MX2010007842A patent/MX2010007842A/es active IP Right Grant
- 2009-01-16 CA CA2711529A patent/CA2711529C/en not_active Expired - Fee Related
- 2009-01-16 CL CL2009000089A patent/CL2009000089A1/es unknown
- 2009-01-16 CN CN201310143383.3A patent/CN103483236B/zh active Active
- 2009-01-16 SI SI200931552A patent/SI2245009T1/sl unknown
- 2009-01-16 HU HUE09702021A patent/HUE030606T2/en unknown
- 2009-01-16 RU RU2010133903/04A patent/RU2513521C2/ru not_active IP Right Cessation
- 2009-01-16 CN CN2009801061724A patent/CN101952249B/zh active Active
- 2009-01-16 WO PCT/EP2009/050510 patent/WO2009090251A2/en active Application Filing
- 2009-01-16 US US12/863,213 patent/US8580974B2/en active Active
- 2009-01-16 KR KR1020107018152A patent/KR101587668B1/ko not_active IP Right Cessation
- 2009-01-16 EP EP09702021.8A patent/EP2245009B1/en active Active
-
2010
- 2010-06-28 IL IL206664A patent/IL206664A0/en unknown
- 2010-06-30 TN TN2010000304A patent/TN2010000304A1/fr unknown
- 2010-06-30 MA MA32970A patent/MA31951B1/fr unknown
- 2010-07-16 GT GT201000211A patent/GT201000211A/es unknown
- 2010-08-12 CO CO10099278A patent/CO6290677A2/es active IP Right Grant
- 2010-08-17 EC EC2010010405A patent/ECSP10010405A/es unknown
-
2013
- 2013-10-31 RU RU2013148670A patent/RU2636936C2/ru not_active IP Right Cessation
- 2013-11-06 JP JP2013230570A patent/JP5800882B2/ja active Active
- 2013-11-11 US US14/076,302 patent/US9061973B2/en active Active
-
2015
- 2015-05-18 US US14/715,129 patent/US9227934B2/en active Active
- 2015-11-12 US US14/939,513 patent/US9403766B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000089A1 (es) | Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras. | |
UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
UY32142A (es) | Preparación de una quinoliniloxidifenilciclopropanodicarboxamida | |
EA201270550A1 (ru) | Процесс получения соединений для применения в качестве ингибиторов sglt2 | |
EA200702614A1 (ru) | Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот | |
UY31367A1 (es) | Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica | |
PE20100487A1 (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
MX340573B (es) | Proceso para la fabricacion de compuestos farmaceuticamente activos. | |
MA31080B1 (fr) | Dérivés cyclisés en tant qu'inhibiteurs d'eg-5. | |
CY1115623T1 (el) | Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
AU2009310099A8 (en) | Agricultural compositions | |
NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
ES2721662T3 (es) | Proceso para la preparación de travoprost | |
PT2462098E (pt) | Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico | |
MX2010009876A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente. | |
BR112014019961A8 (pt) | Processo telescópico (de recipiente único sequencial) para sintetizar sal de 5-amino-4-nitroso-1-alquil-1h-pirazol e para produção de um sal de 4,5-diamino-1-alquil-pirazol | |
UA113223C2 (xx) | Арилетинілпіримідини | |
EA201592167A1 (ru) | Способ получения производных пирролидин-2-карбоновой кислоты | |
UY33507A (es) | Proceso para la preparacion de sales de enolato de 4-fluoro-2-hidroximetileno-3-oxo-butiratos | |
WO2012052939A3 (en) | Preparation of bicyclo[2.2.2]octan-2-one compounds | |
MX2013004425A (es) | Preparacion diastereoselectiva de los compuestos de biciclo [2.2.2] octan-2-ona. | |
SG162815A1 (en) | Process for preparing benzimidazole compounds | |
ES2421641T3 (es) | Procedimiento para la preparación de valsartan | |
EA201200183A1 (ru) | Производные бензамида, их получение и применение |